Radioactive treatment for bone pain in advanced prostate cancer tested, but study stopped early
NCT ID NCT04616547
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a radioactive drug called Sn-117m-DTPA to see if it could reduce bone pain in men with prostate cancer that had spread to their bones and no longer responded to hormone therapy. Only one person enrolled before the study was stopped. The goal was to measure pain relief over several weeks and check for side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CASTRATION-RESISTANT PROSTATE CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Kentucky/Markey Cancer Center
Lexington, Kentucky, 40536, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug tame metastatic prostate cancer? a phase 1 trial aims to find out
- Can a tracer that hunts unstable iron light up hidden tumors?
- Can a three-drug cocktail outsmart resistant prostate cancer?
- Precision radiation may tame rising PSA after prostate surgery
- New prostate cancer drug HRS-7525 enters first human tests
- Real-Time nerve monitoring during spine surgery could predict bladder and bowel function